» Articles » PMID: 30423871

Non-Alcoholic Fatty Liver Disease Among Type-2 Diabetes Mellitus Patients in Abha City, South Western Saudi Arabia

Overview
Publisher MDPI
Date 2018 Nov 15
PMID 30423871
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to determine the prevalence and the factors associated with non-alcoholic fatty liver disease (NAFLD) among type-2 diabetes mellitus (T2DM) patients in Abha City, Southwestern Saudi Arabia. Using a cross-sectional study design, a representative sample of 245 T2DM patients were recruited from all primary healthcare centers in Abha city. A detailed medical history as well as laboratory investigations were done. NAFLD was diagnosed using abdominal ultrasound examination. The overall prevalence of NAFLD was 72.8% (95% CI: 66.6%⁻78.1%). In a multivariable regression analysis, the risk of NAFLD was significantly higher among overweight T2DM patients (aOR = 6.112, 95% CI: 1.529⁻4.432), Obese (aOR = 10.455, 95% CI: 2.645⁻41.326), with high ALT of more than 12 IU/L (aOR = 2.335, 95% CI: 1.096⁻5.062), moderate diet-compliant patients (aOR = 2.413, 95% CI: 1.003⁻5.805) and poor diet-compliant patients (aOR = 6.562, 95% CI: 2.056⁻20.967). On the other hand, high HDL (high density cholesterol) (in mg/dL) was a protective factor for NAFLD (aOR = 0.044, 95% CI: 0.005⁻0.365). It was concluded that NAFLD is a common association of T2DM. Increasing BMI (Body mass index), lower HDL level, and poor dietary control are significant factors associated with NAFLD among T2DM patients. Health education to improve dietary control and avoid excessive weight gain, testing for NAFLD among diabetic patients, especially those with abnormal BMI and HDL, are recommended for early detection and to ensure optimal levels of HDL.

Citing Articles

A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities.

Al-Omar H, Alshehri A, Alqahtani S, Alabdulkarim H, Alrumaih A, Eldin M Saudi Pharm J. 2024; 32(11):102192.

PMID: 39525490 PMC: 11550078. DOI: 10.1016/j.jsps.2024.102192.


Assessment of Liver Involvement in Patients With Type 2 Diabetes Mellitus in Basrah City, Iraq, Using FibroScan and Correlation With Risk Factors.

Abdullah M, Kadhum F, Issa S Cureus. 2024; 16(7):e65089.

PMID: 39171003 PMC: 11337731. DOI: 10.7759/cureus.65089.


Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) Among Diabetic Mellitus Patients in Saudi Arabia: Systematic Review and Meta-Analysis.

Albeshry A, Abdulrahman Alasmari M, Alshahrani J, Alshahrani A, Saad Almusma A, Alfaya M Cureus. 2024; 15(12):e51092.

PMID: 38283461 PMC: 10810724. DOI: 10.7759/cureus.51092.


The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review.

Aldossari K Afr Health Sci. 2024; 23(2):509-518.

PMID: 38223606 PMC: 10782311. DOI: 10.4314/ahs.v23i2.59.


Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Saudi Arabia: Systematic Review and Meta-analysis.

Alenezi Y, Harris R, Morling J, Card T Cureus. 2023; 15(6):e40308.

PMID: 37448425 PMC: 10337700. DOI: 10.7759/cureus.40308.


References
1.
Younossi Z . Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008; 28(1):2-12. DOI: 10.1111/j.1365-2036.2008.03710.x. View

2.
Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson L . Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3):865-72. DOI: 10.1053/j.gastro.2009.06.005. View

3.
Spengler E, Loomba R . Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc. 2015; 90(9):1233-46. PMC: 4567478. DOI: 10.1016/j.mayocp.2015.06.013. View

4.
Poanta L, Albu A, Fodor D . Association between fatty liver disease and carotid atherosclerosis in patients with uncomplicated type 2 diabetes mellitus. Med Ultrason. 2011; 13(3):215-9. View

5.
Banderas D, Escobedo J, Gonzalez E, Liceaga M, Ramirez J, Castro M . γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012; 24(7):805-10. DOI: 10.1097/MEG.0b013e328354044a. View